completed

EPIC STEMI was a randomized, double-blind, placebo controlled parallel group clinical trial evaluating the effects of acute treatment with a PCSK9 inhibitor, alirocumab, versus placebo, on low-density lipoprotein (LDL) in 100 high-risk patients presenting with STEMI and referred for primary PCI.

The objective was to determine the effect of acute, rapid lowering of LDL cholesterol with alirocumab added to high dose statin therapy in patients with STEMI undergoing primary PCI.

The hypothesis was that in patients with STEMI undergoing primary PCI, rapid lowering of LDL cholesterol with a PCSK9 inhibitor (alirocumab) – initiated in the acute setting pre-PCI – will favourably affect LDL cholesterol concentrations compared with placebo.

EPIC STEMI, TCT 2022 (download PDF)
Study Type

Interventional - Drug

Study Design

A randomized, double-blind, placebo RCT

NO. of Countries

1

NO. of Sites

1

NO. of Participants

100

Study Period

2019 - 2021

Sponsor

PHRI

Sanofi

Shamir Mehta at TCT 2022

VIDEO: Shamir Metha on EPIC STEMI with C. Michael Gibson at TCT 2022

Back To Top